Ronald G Spaeth Net Worth

The estimated Net Worth of Ronald G Spaeth is at least $247 ezer dollars as of 30 July 2013. Ronald Spaeth owns over 4,000 units of Stericycle stock worth over $246,680 and over the last 16 years Ronald sold SRCL stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ronald Spaeth SRCL stock SEC Form 4 insiders trading

Ronald has made over 2 trades of the Stericycle stock since 2012, according to the Form 4 filled with the SEC. Most recently Ronald exercised 4,000 units of SRCL stock worth $235,280 on 30 July 2013.

The largest trade Ronald's ever made was exercising 7,033 units of Stericycle stock on 8 August 2012 worth over $349,962. On average, Ronald trades about 1,379 units every 45 days since 2008. As of 30 July 2013 Ronald still owns at least 4,000 units of Stericycle stock.

You can see the complete history of Ronald Spaeth stock trades at the bottom of the page.

What's Ronald Spaeth's mailing address?

Ronald's mailing address filed with the SEC is 28161 N. KEITH DRIVE, , LAKE FOREST, IL, 60045.

Insiders trading at Stericycle

Over the last 22 years, insiders at Stericycle have traded over $161,740,081 worth of Stericycle stock and bought 27,280 units worth $1,574,920 . The most active insiders traders include Jack W Schuler, John Connaughton és James Reid Anderson. On average, Stericycle executives and independent directors trade stock every 23 days with the average trade being worth of $835,752. The most recent stock trade was executed by Jesse Joel Jr Hackney on 16 May 2024, trading 3,620 units of SRCL stock currently worth $223,245.

What does Stericycle do?

stericycle is a global services company. we provide highly specialized solutions serving healthcare organizations and commercial businesses of every size and shape. throughout the last 25 years, we have grown from a small start-up in medical waste management into a leader across a range of increasingly complex and highly regulated arenas, such as: • brand protection solutions • environmental & sustainable solutions • patient & customer communication solutions • regulated waste management & compliance solutions from the start we have challenged the status quo of what a business solution can be. by identifying unmet needs, we have redefined and transformed multiple industries from a narrowly defined service category to a robust suite of solutions that customers need and want. our success with this strategy has landed stericycle among the fortune 1000 list and forbes 25 most innovative companies. a publicly-traded company with $2.5 billion in 2014 revenue, our core purpose is to

Complete history of Ronald Spaeth stock trades at Stericycle

Stericycle executives and stock owners

Stericycle executives and other stock owners filed with the SEC include:

• Cindy Miller,
  President, Chief Executive Officer, Director
• Cindy J. Miller,
  Pres, CEO & Director
• Janet H. Zelenka,
  Exec. VP, CFO & Chief Information Officer
• Daniel Ginnetti,
  Executive Vice President - International
• Janet Zelenka,
  Chief Financial Officer, Executive Vice President, Chief Information Officer
• Kurt Rogers,
  Executive Vice President, General Counsel and Corporate Secretary
• Joseph Reuter,
  Executive Vice President and Chief People Officer
• Stephen Cory White,
  Exec. VP & Chief Commercial Officer
• Kurt M. Rogers,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Robert Murley,
  Independent Chairman of the Board
• Brian Anderson,
  Independent Director
• Lynn Bleil,
  Independent Director
• Michael Zafirovski,
  Independent Director
• Kay Priestly,
  Independent Director
• Veronica Hagen,
  Independent Director
• Thomas Chen,
  Independent Director
• J. Joel Hackney,
  Independent Director
• Stephen Hooley,
  Independent Director
• S. Cory White,
  Executive Vice President and Chief Commercial Officer
• Richard Moore,
  Executive Vice President - North American Operations
• Dominic Culotta,
  Executive Vice President and Chief Engineer
• Michael Weisman,
  Executive Vice President, Chief Ethics and Compliance Officer
• Richard Michael Moore,
  Exec. VP of North American Operations
• Joseph Anthony Reuter,
  Exec. VP & Chief People Officer
• Michael S. Weisman,
  Exec. VP and Chief Ethics & Compliance Officer
• Andrew Ellis,
  VP of Investor Relations
• Daniel V. Ginnetti,
  Exec. VP of International
• Jennifer Koenig,
  VP of Corp. Communications & Investor Relations
• Richard Joseph Hoffman,
  Sr. VP & Chief Accounting Officer
• Richard J Hoffman,
  SVP & CHIEF ACCOUNTING OFFICER
• John P Schetz,
  Sr Counsel M & A
• Thomas D Brown,
  Director
• Mike S Zafirovski,
  Director
• John Patience,
  Director
• Jack W Schuler,
  Chairman
• Brenda R Frank,
  EVP & Chief People Officer
• Brent Arnold,
  President, USA/Canada
• Ruth Ellen Abdulmassih,
  Executive Vice President
• Rodney F Dammeyer,
  Director
• Charles A Alutto,
  President, USA
• Robert Guice,
  Executive Vice President, Intl
• David W. Stahl,
  EVP and CIO
• William J. Seward,
  EVP, Chief Commercial Officer
• James Reid Anderson,
  Director
• Mark C Miller,
  CEO
• Michael J Collins,
  President, Pharma Services
• Shan Sacranie,
  Exec Vice Pres International
• Richard L Foss,
  EXVP
• Richard T Kogler,
  COO
• Richard J Marasco,
  Exec VP Corp Mergers & Acquis
• Thomas R Reusche,
  Director
• L John Wilkerson,
  Director
• Jonathan T Md Lord,
  Director
• Peter Vardy,
  Director
• Brink Frank Jm Ten,
  CFO
• William K Hall,
  Director
• Ronald G Spaeth,
  Director
• Patrick F Graham,
  Director
• Anthony J Tomasello,
  Vice President
• James J Martell,
  Director
• John Connaughton,
  Director
• James L Welch,
  
• Victoria L Dolan,
  
• Naren K Gursahaney,